#United States #Plainfield #Waters Corporation #HPV Screening #SNT Biotech

SNT Biotech's Innovative Partnership for Women's Health

SNT Biotech, a leading population health technology company, has made headlines with its recent collaboration with Waters Corporation. This partnership introduces a groundbreaking at-home HPV cervical cancer screening tool, designed to expand access to preventive care for women across the U.S. This initiative comes on the heels of receiving FDA clearance for The Onclarity™ HPV Self-Collection Kit, enabled by the BD Onclarity™ HPV Assay, marking a significant milestone in women's health technology.

Every year, approximately 4,000 women in the United States fall victim to cervical cancer, a disease that is often preventable through routine screenings. Alarmingly, about 60% of diagnoses are found in individuals who have either never been screened or are inadequately screened, underscoring the barriers that still exist in the healthcare system. SNT Biotech aims to address these challenges by providing innovative solutions that simplify and enhance access to preventative care.

Expanding Access Through Innovation

The Onclarity™ HPV Self-Collection Kit is heralded as the most comprehensive at-home cervical cancer screening tool currently available. With a commitment to making women's health screenings more accessible, SNT Biotech's approach is particularly timely, offering women alternatives to traditional clinic visits. Given federal guidelines, many insurers are expected to offer self-collected HPV screenings at no cost to members starting in 2027.

SNT Biotech's commercialization strategy is designed to assist health plans, managed care organizations, and Federally Qualified Health Centers in improving cervical cancer screening rates among members who face the most difficulties in accessing healthcare services. This initiative focuses on delivering the Self-Collection Kit directly to women who are overdue for screening, thus helping to close the gaps in cervical cancer prevention.

Leveraging Technology for Improved Engagement

One of the significant obstacles in at-home health screenings has been low return rates for completed kits. SNT Biotech is addressing this by employing a fully integrated population health model. This model encompasses patient outreach through a variety of channels including text, email, and live calls, all conducted in multiple languages. With dedicated efforts to ensure that women are engaged throughout their screening journey, from kit delivery to lab analysis, SNT Biotech is poised to enhance completion rates significantly.

The results of the tested kits are then shared with women, their primary care physicians, and health plan quality teams, ensuring a comprehensive approach to data dissemination and patient education. The use of real-time program dashboards allows for accountability and transparency within the screening process, boosting health plans' ability to increase participation and improve health outcomes.

A Call for Action

Shital Daftari, the founder and CEO of SNT Biotech, expressed enthusiasm about the partnership with Waters Corporation, highlighting the need to provide better access to health screenings. "We are solving a vital issue for women who need screenings the most, often with limited accessibility. Our solution combines education, accessibility, and insights to transform how preventative care is delivered," Daftari stated.

Dr. Jeff Andrews from Waters Corporation also emphasized the importance of broadening access to cervical cancer screenings, mentioning that the Onclarity™ HPV Self-Collection Kit is a comprehensive solution that provides critical information for healthcare professionals. He underlined the necessity of eliminating barriers to screenings, as every 90 seconds a woman loses her life to cervical cancer despite its preventability.

In a similar vein, Dr. Yvonne Collins, a gynecologic oncologist, articulated the potential of this approach to revolutionize how vulnerable populations access care, further stating, "At-home HPV testing has the capacity to transform our screening population by reducing barriers and enabling earlier disease detection."

Looking Forward

As a minority and women-owned business, SNT Biotech is dedicated to advancing access to preventive healthcare. By partnering with organizations that share their commitment to improving health outcomes, they aim to bridge the gaps in access to care while supporting education and early detection efforts. Their efforts not only pave the way for innovations in technology but also reflect a deeper understanding of the healthcare landscape and its challenges.

In conclusion, SNT Biotech's initiative represents a significant leap towards enhancing women's health services nationwide, ensuring that every woman has the opportunity to screen for cervical cancer in a way that respects her circumstances and accessibility needs. This partnership heralds a new era of population health management, one where technology and compassionate care come together for the benefit of all.